Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
The last earnings update was 144 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Amplia Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Amplia Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amplia Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Amplia Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Amplia Therapeutics's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Amplia Therapeutics's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Amplia Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if Amplia Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Amplia Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Amplia Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Amplia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Amplia Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
Amplia Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Amplia Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. John Lambert has been the Chief Executive Officer at Amplia Therapeutics Limited since June 24, 2019. Dr. Lambert served as Vice President of Drug Development at Biota Pharmaceuticals, Inc. Dr. Lambert has been Consultant to Biota Holdings over year and a collaborator on one of Biota's new technology-based projects involving the application of FLUNET technology to new targets. He served as Vice President of Product Development Operations at Biota Holdings Ltd. He served as Principal Director of Product Development Operations for Biota Holdings Ltd. He served as Executive Director of Drug Discovery at Biota Holdings Ltd. and served as its Director of U.S Research. Dr. Lambert was responsible for research activities undertaken by Biota Inc., and oversees the transfer of these research programs to the Australian laboratories. He is nationally and internationally recognized Chemist. He co-founded Cryptopharma Pty Ltd. in 2000 and serves as its Director. He is a Member of the Royal Australian Chemical Institute and the American Chemistry Society and is Editor-in-Chief of Chemistry in Australia. His most recent appointment was Senior Lecturer at Melbourne University. He has published widely on his original research, much of which has been in areas of potential for medical applications. He has been recipient of many other distinguished awards for his contributions to chemistry including the inaugural Cornforth Medal in 1993 and the Selby Research Award in 1996. Dr. Lambert graduated from the University of Melbourne and undertook post-doctoral studies at the Harvard University Chemical Laboratories, USA and the Australian National University where he held a Queen Elizabeth II Fellowship.
Insufficient data for John to compare compensation growth.
John's remuneration is lower than average for companies of similar size in Australia.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Amplia Therapeutics management team is about average.
Chief Executive Officer
Chief Financial Officer
Company Secretary & Independent Non-Executive Director
Chief Scientific Advisor
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Amplia Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Company Secretary & Independent Non-Executive Director
Independent Non-Executive Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Amplia Therapeutics individual insiders in the past 3 months, but not in substantial volumes.
What Type Of Shareholder Owns Amplia Therapeutics Limited's (ASX:ATX)?
Our analysis of the ownership of the company, below, shows that institutions don't own many shares in the company. … Check out our latest analysis for Amplia Therapeutics ASX:ATX Ownership Summary, May 31st 2019 What Does The Institutional Ownership Tell Us About Amplia Therapeutics? … Insider Ownership Of Amplia Therapeutics The definition of an insider can differ slightly between different countries, but members of the board of directors always count.
If You Had Bought Amplia Therapeutics (ASX:ATX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today
Anyone who held Amplia Therapeutics Limited (ASX:ATX) for five years would be nursing their metaphorical wounds since the share price dropped 94% in that time. … View our latest analysis for Amplia Therapeutics. … With zero revenue generated over twelve months, we don't think that Amplia Therapeutics has proved its business plan yet.
Is Amplia Therapeutics Limited's (ASX:ATX) CEO Pay Fair?
How Does Simon Wilkinson's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Amplia Therapeutics Limited has a market cap of AU$5.1m, and is paying total annual CEO compensation of AU$336k. … We examined a group of similar sized companies, with market capitalizations of below AU$282m
How Financially Strong Is Amplia Therapeutics Limited (ASX:ATX)?
The direct benefit for Amplia Therapeutics Limited (ASX:ATX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is ATX right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
Does Amplia Therapeutics Limited's (ASX:ATX) CEO Salary Compare Well With Others?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Simon Wilkinson's Compensation Compare With Similar Sized Companies. … According to our data, Amplia Therapeutics Limited has a market capitalization of AU$9.4m, and pays its CEO total annual compensation worth AU$336k.
Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits FAK. The company also manufactures and sells drugs. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in North Melbourne, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.